VELASOF TABLET 28'S

VELASOF TABLET 28'S has shown efficacy in treating hepatitis C in individuals with advanced liver disease or compensated cirrhosis. However, the response rate may vary, and close monitoring of liver function is important during and after treatment.

Yes, regular blood tests are typically conducted during VELASOF TABLET 28'S treatment to monitor liver function, viral load, and treatment response. These tests help assess the effectiveness of the medication and ensure patient safety.

VELASOF TABLET 28'S can be used in patients with mild to moderate kidney impairment without dose adjustment. However, patients with severe renal impairment or end-stage renal disease may require dose adjustments or alternative treatment options. It is important to discuss your kidney function with your healthcare provider to determine the most appropriate treatment plan.

VELASOF TABLET 28'S is effective and safe in individuals with both hepatitis C and HIV co-infection. However, it is important to coordinate treatment with both infectious disease and HIV specialists to ensure proper management of both conditions.

Weight gain or loss is not commonly reported as a side effect of VELASOF TABLET 28'S. However, individual responses to medication can vary. If you experience any unexplained or concerning changes in weight during treatment, it is recommended to consult your healthcare provider for further evaluation.

VELASOF TABLET 28'S can be used in patients with a history of liver transplantation who have recurrent hepatitis C. However, individual patient factors and the specific post-transplantation period must be considered. Consultation with a transplant hepatologist or specialist is recommended to determine the most appropriate treatment approach.

While VELASOF TABLET 28'S is generally well-tolerated, like any medication, it can potentially cause side effects. Common side effects include headache, fatigue, nausea, and insomnia. Serious side effects are rare but can include severe allergic reactions, changes in heart rate, and liver problems. It is important to discuss any concerns or potential side effects with your healthcare provider, who can provide further information and guidance based on your specific situation.

It is important to inform your healthcare provider about all current medications due to potential drug interactions. Individuals taking amiodarone should be closely monitored for severe bradycardia (decreased heart rate) when co-administered with VELASOF TABLET 28'S.

Yes, before starting treatment, screening for hepatitis B virus (HBV) infection is recommended due to the risk of reactivation. Close monitoring of liver function and HBV DNA levels is necessary during and after treatment for those with current or prior HBV infection. Dose adjustments may be needed for patients with severe kidney problems. Discuss psychiatric health, pregnancy, and breastfeeding with your doctor.

VELASOF TABLET 28'S contains the active ingredients SOFOSBUVIR and VELPATASVIR.

VELASOF TABLET 28'S is primarily prescribed for the treatment of chronic Hepatitis C virus (HCV) infection.

VELASOF TABLET 28'S is a combination of antiviral medications (Sofosbuvir and Velpatasvir) that work by preventing the Hepatitis C virus from multiplying in the body, helping to clear the infection.

VELASOF TABLET 28'S is effective against all major genotypes (1-6) of the Hepatitis C virus.